New technique may help detect potential breast cancer spread
...d Lymphoseek. Twenty-eight percent of the lymph nodes were positive for cancer, 100 percent of which were detected by Lymphoseek.
"The advantage in lymphoseek
is that we now have an agent that is tested and designed specifically for detection of sentinel lymph nodes," Wallace said, noting that blue dye is no...
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation
(OTCBB:NEOP), a diversified developer of innovative oncology and
cardiovascular surgical and diagnostic products, today announced
positive preliminary results from a multicenter Phase 2 clinical
study of its lead clinical candidate,...
Neoprobe Corporation - Innovations in Care... Improvements in Lives
Neoprobe, dedicated to improving the diagnosis and treatment of cancer, develops products based on radio-guided ... and Stomach Using Lymphoseek
in a Pig ...
May 7, 2009Lymphoseek
that included a mixed population of clinically node-negative breast cancer and ... the accuracy of Lymphoseek
, each patient ...
Neoprobe Commences Lymphoseek Phase 3 Trial
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that a ...
Neoprobe's Phase 3 Lymphoseek Study Achieves Positive Results
... diagnostic products, announced that a multicenter Phase 3 study of Lymphoseek
® ... Lymphoseek
is a proprietary radioactive tracing agent being developed ...
Neoprobe Corporation Receives Clearance For Additional Lymphoseek ...
Neoprobe Corporation (NEOP) Receives Clearance For Additional Lymphoseek
Trials. 1/17/2007 ... safety and efficacy of Lymphoseek
®, a lymphatic tissue targeting ...
Neoprobe Announces Funding Milestone Reached | Reuters
Company to Receive $3 Million Based on Lymphoseek
Phase 3 Clinical Achievement DUBLIN, Ohio--(Business Wire)-- Neoprobe Corporation (OTCBB:NEOP), a diversified ...